7
 2 EN This package insert must be read carefully prior to use. Package insert instructions must be followed accordingly. No deviations from the instructions in this package insert are allowed. NAME AND INTENDED USE  Alere Determine™ TB LAM Ag is an In Vitro, visually read, qualitative immunoassay for the detection of lipoarabinomannan (LAM) antigen of Mycobacteria in human urine as an aid in the diagnosis of active mycobacterial infection in HIV positive individuals with clinical symptoms of tuberculosis. INTRODUCTION Tuberculosis (TB) is a multifaceted disease and challenging public health problem in both industrialized and developing countries. TB control programs are currently facing a number of constraints. Worldwide, fewer than 25% of all tuberculosis cases are detected. Of utmost concern is the absence of a timely and accurate test for the diagnosis of mycobacterial disease. Early diagnosis is essential in preventing the further spread of TB 1 . Current standard TB diagnostic tests have several well documented weaknesses. Even in controlled research settings, the average sensitivity of sputum microscopy for pulmonary tuberculosis is only 67% and is substantially lower among people infected with HIV 2 . Conventional culture methods are so slow that testing often loses clinical relevance and the poor predictive value of the tuberculin skin test renders it essentially worthless in disease-endemic areas. The weaknesses of these available diagnostic technologies are only amplied in high-burden countries, which typically suffer from inadequate infrastructure and stafng. In addition, sputum based microbiological assays are unable to detect extrapulmonary TB infection, a clinical manifestation that occurs more frequently in high-HIV endemic areas. Another major obstacle is the diagnosis of tuberculosis in children. Sputum based methodologies are often hampered by the inability of small children to generate sputum.  Alere Determine™ TB LAM Ag requires only a urine sample and is complete in 25 minutes. BIOLOGICAL PRINCIPLES OF THE PROCEDURE  Alere Determine™ TB LAM Ag is an immunochromatographic test for the qualitative detection of lipoarabinomannan (LAM) antigen of Mycobacteria in human urine.  Alere Determine™ TB LAM  Ag employs highly puried antibodies specic to the major p olysaccharide antigen of the genus Mycobacterium: lipoarabinomannan (LAM). These antibodies are used for both the capture and the detection tracer. The capture antibodies are adsorbed onto the nitrocellulose membrane of the test strip. The detection antibody is labeled by conjugation to colloidal gold particles.  After a urine specimen is added to the sample pad, the colloidal gold conjugated antibodies attach to the LAM antigen and are released by the specimen from the conjugate pad. This immunological complex is then captured by anti LAM antibodies immobilized on the nitrocellulose membrane and made visible due to the presence of the colloidal gold label. A positive result (a visible purple/gray line) indicates that LAM antigen of Mycobacteria is present in the sample at or above the detection limit of the test; whereas a negative result (no visible purple/gray line) indicates it is not present or below detection limit. To ensure assay validity, a procedural control bar is incorporated in the assay device. LIMITATIONS OF THE PROCEDURE  Alere Determine™ TB LAM Ag is designed to detect Mycobacterial LAM antigen in human urine. Other samples (e.g. sputum, serum, plasma, CSF or other body uids) or pooled urine specimens should not be used.  Alere Determine™ TB LAM Ag does not differentiate between the various species of Mycobacterium, such as M. tuberculosis, M. leprae, and M. avium. In an area endemic for tuberculosis the LAM antigen detected in a clinical sample is likely to be attributed to M. tuberculosis. • No test provides absolute assurance tha t a specimen does not contain low levels of LAM antigen such as those present at a very early stage of infection. A negative result does not preclude the possibility of infection with M. tuberculosis. • No test is 100% specic. Positive results should be evaluate d in light of the overall clinic al evaluation before a diagnosis is made.  Alere Determine™ TB LAM Ag should be followed up with conrmation test such as bacterial culture and with a drug susceptibility test, if possible. • The intensity of the patient bar does not necessarily correlate to the bacterial burden. • Testing diuretic urine may affect the ability of the test to detect LAM antigen in u rine of TB patients. • Excretion of LAM antigen in urin e may vary depending on the individual patient's condition and his underlying illness or treatment. The effect of treatment of the patient with broad-spectrum antibiotics on the  Alere Determine™ TB LAM Ag test performance has not been established. CONTENTS  Alere Determine™ TB LAM Ag Test Card, 10 cards (10 tests/card) ACCESSORIES (required but not provided) Urine collection cups  A 60 µl MICROSAFE CA PILLARY TUBE  (7D2224) EQUIPMENT (required but not provided) • Pipette capable of accurately delivering 60 µL and disposable pipette tips. • Timer WARNINGS AND PRECAUTIONS For In Vitro  diagnostic use. For professional use only. Safety data sheet available for professional user on request. CAUTION:  Any clinical specimen from any patient should be considered potentially infectious material and has to be handled according to institutional guidelines for handling such materials.  Appropriate biosafety practices 3,4  should be used when handling specimens and reagents. These precautions include, but are not limited to the following: • Wear gloves. • Do not pipette by mouth. • Do not eat, drink, smoke, apply cosmetics, or handle contact lenses in areas where these materials are handled. • Clean and disinfect all spills of specimens or reagents using suitable disinfecta nt, such as 0.5% sodium hypochlorite, or other suitable disinfectant. 3 • Decontaminate and dispose of all specimens, reagents, and other potentially contaminated materials in accordance with local regulations. 3,4 STORAGE  Alere Determine™ TB LAM Ag test cards must be stored at 2-30°C until the expiration date. • Kit components are stable u ntil expiration date when handled and stored as directe d. Do not use kit TB LAM Ag Determine™ December 2013 02740004/05 TEST PROCEDURE The desired number of test units from the 10-test card can be removed by bending and tearing at the perforation. NOTE: • Removal of the test units should start from the right side of the test card to preserve the lot number which appears on the left side of the test card. • The assay should be initiated within 2 hours after removing the protective foil cover from each test. 1. Remove the protective foil cover from each test. 2. Apply 60 µL of sample (precision pipette) to the sample pad (White pad marked by the arrow symbol). A 60 µl MICROSAFE CA PILLARY TUBE  can be used (refer to the Microsafe Capillary Tube package insert for additional information). 3. Wait a minimum of 25 minutes and read result. Visualize the strip under standard indoor lighting conditions or in the shade. Do not visualize the strip under direct sun light. Results are stable for up to 35 minutes after sample application. Do not read beyond 35 minutes. QUALITY CONTROL To ensure assay validity, a procedural control is incorporated in the device and is labeled “Control”. If the control bar does not turn purple/gray by assay completion, the test result is invalid and the sample should be retested. INTERPRETATION OF RESULTS To assist with results reading and interpretation use the Reference Scale Card (provided in the kit) by holding it alongside the patient window. LAM Antigen POSITIVE (Two Bars - Control and Patient Bars) Purple/gray bars appear in both the control window (labeled “Control”) and the Patient window (labeled “Patient”) of the strip. The color intensity of the “Patient” bar should be equal to, or stronger than, any of the colored bars in the “POSITIVE” range on the Reference Scale Card. Note: The test result is positive even if the patient bar appears lighter or darker than the control bar, as long as the “Patient” bar is equal to or stronger than any of the colored bars in the “POSITIVE” range on the Reference Scale Card. NEGATIVE (One Bar) One purple/gray bar appears in the control window of the strip (labeled “Control”) and no purple/gray bar appears in the Patient window of the strip (labeled “Patient”). INVALID (No Bar) If there is no purple/gray bar in the control window of the strip, even if a purple/gray bar appears in the patient window of the strip, the result is invalid and the test should be repeated. If the problem persists, contact your local distributor or call  Alere Technical Support as detailed below. EQUIVOCAL/INDEFINITE: One purple/gray bar appears in the Control window of the strip (labeled “Control”) with unclear or incomplete purple/gray bar in the Patient window of the strip (labeled “Patient”) OR: if the color intensity of the bar in the “Patient” window is lower than any of the colored bars in the “POSITIVE” range on the Reference Scale Card. For a better clinical decision the test should be repeated. Alternatively, collect a new urine sample from the patient in the following days and test. First or early morning urine is recommended. PERFORMANCE CHARACTERISTICS The performance of  Alere Determine™ TB LAM Ag test has been determined by testing urine specimens from HIV positive patients with suspected TB infection. The performance evaluations were conducted in prospective clinical studies in South Africa. Prospective study versus sputum culture The diagnostic accuracy of the  Alere Determine™ TB LAM Ag for screening for HIV-associated pulmonary tuberculosis was evaluated in a prospective study in HIV infected outpatients newly referred to ART (antiretroviral therapy) clinic in Cape Town, South Africa 5 . Of 516 patients with complete data information, 85 had positive TB diagnosis based on positive TB sputum culture. The  Alere Determine™ TB LAM Ag sensitivity compared to sputum culture was strongly associated with the patients‘ CD4 cell count with the highest sensitivity at low CD4 cell counts: 66.7% at <50 cells/μL, 51.7% at <100 cells/μL, and 39.0% at <200 cells/μL. An additive effect occurred when the  Alere Determine™ TB LAM Ag results were combined with sputum smear microscopy (39.0% and 30.5% sensitivities respectively) reaching sensitivity of 52% amongst patients with CD4 counts below 200 cells/µL. Of 431 patients with negative sputum cultures only 6 tested positive on the Alere Determine™ TB LAM Ag test yielding a specicity of 98.6% versus culture. Prospective study versus TB diagnosis based on composite criteria The diagnostic accuracy of the Alere Determine™ TB LAM Ag for TB detection in hospitalised HIV infected patients with advanced immunosuppression was evaluated in a prospective study in Cape Tow n, South Africa 6 . Of 214 patients with complete data information, 187 were considered TB positive according to composite criteria (denite or probable TB). The overall sensitivity of the  Alere Determine™ TB LAM Ag test was 45% in this patient group, improving to 52% in patients with CD4 cell count 200 cells/μl. The sensitivity in smear negative/sputum scarce HIV-infected TB patients was 39%, improving to 51% in HIV-infected patients with a CD4 cell count 200 cells/μl, and 58% when the CD4 cell count was 100 cells/μl.  An additive effect occurred when the  Alere Determine™ TB LAM Ag results were combined with sputum smear microscopy providing sensitivity of 63% (smear microscopy sensitivity 44%). The Alere Determine™ TB LAM Ag specicity was 96% (27 patients). An additional 88 HIV positive/TB negative control patients had specicity of 99%.

Package insert

Embed Size (px)

DESCRIPTION

lateral flow

Citation preview

  • 2ENThis package insert must be read carefully prior to use. Package insert instructions must be followed accordingly. No deviations from the instructions in this package insert are allowed.

    NAME AND INTENDED USE

    Alere Determine TB LAM Ag is an In Vitro, visually read, qualitative immunoassay for the detection of lipoarabinomannan (LAM) antigen of Mycobacteria in human urine as an aid in the diagnosis of active mycobacterial infection in HIV positive individuals with clinical symptoms of tuberculosis.

    INTRODUCTION

    Tuberculosis (TB) is a multifaceted disease and challenging public health problem in both industrialized and developing countries. TB control programs are currently facing a number of constraints. Worldwide, fewer than 25% of all tuberculosis cases are detected. Of utmost concern is the absence of a timely and accurate test for the diagnosis of mycobacterial disease. Early diagnosis is essential in preventing the further spread of TB1.

    Current standard TB diagnostic tests have several well documented weaknesses. Even in controlled research settings, the average sensitivity of sputum microscopy for pulmonary tuberculosis is only 67% and is substantially lower among people infected with HIV2. Conventional culture methods are so slow that testing often loses clinical relevance and the poor predictive value of the tuberculin skin test renders it essentially worthless in disease-endemic areas. The weaknesses of these available diagnostic technologies are only amplified in high-burden countries, which typically suffer from inadequate infrastructure and staffing. In addition, sputum based microbiological assays are unable to detect extrapulmonary TB infection, a clinical manifestation that occurs more frequently in high-HIV endemic areas. Another major obstacle is the diagnosis of tuberculosis in children. Sputum based methodologies are often hampered by the inability of small children to generate sputum. Alere Determine TB LAM Ag requires only a urine sample and is complete in 25 minutes.

    BIOLOGICAL PRINCIPLES OF THE PROCEDURE

    Alere Determine TB LAM Ag is an immunochromatographic test for the qualitative detection of lipoarabinomannan (LAM) antigen of Mycobacteria in human urine. Alere Determine TB LAM Ag employs highly purified antibodies specific to the major polysaccharide antigen of the genus Mycobacterium: lipoarabinomannan (LAM). These antibodies are used for both the capture and the detection tracer. The capture antibodies are adsorbed onto the nitrocellulose membrane of the test strip. The detection antibody is labeled by conjugation to colloidal gold particles.

    After a urine specimen is added to the sample pad, the colloidal gold conjugated antibodies attach to the LAM antigen and are released by the specimen from the conjugate pad. This immunological complex is then captured by anti LAM antibodies immobilized on the nitrocellulose membrane and made visible due to the presence of the colloidal gold label. A positive result (a visible purple/gray line) indicates that LAM antigen of Mycobacteria is present in the sample at or above the detection limit of the test; whereas a negative result (no visible purple/gray line) indicates it is not present or below detection limit. To ensure assay validity, a procedural control bar is incorporated in the assay device.

    LIMITATIONS OF THE PROCEDURE

    Alere Determine TB LAM Ag is designed to detect Mycobacterial LAM antigen in human urine. Other samples (e.g. sputum, serum, plasma, CSF or other body fluids) or pooled urine specimens should not be used.

    Alere Determine TB LAM Ag does not differentiate between the various species of Mycobacterium, such as M. tuberculosis, M. leprae, and M. avium. In an area endemic for tuberculosis the LAM antigen detected in a clinical sample is likely to be attributed to M. tuberculosis.

    NotestprovidesabsoluteassurancethataspecimendoesnotcontainlowlevelsofLAMantigensuchas those present at a very early stage of infection. A negative result does not preclude the possibility of infection with M. tuberculosis.

    Notestis100%specific.Positiveresultsshouldbeevaluatedinlightoftheoverallclinicalevaluationbefore a diagnosis is made.

    Alere Determine TB LAM Ag should be followed up with confirmation test such as bacterial culture and with a drug susceptibility test, if possible.

    Theintensityofthepatientbardoesnotnecessarilycorrelatetothebacterialburden.TestingdiureticurinemayaffecttheabilityofthetesttodetectLAMantigeninurineofTBpatients.ExcretionofLAMantigeninurinemayvarydependingontheindividualpatient'sconditionandhis

    underlying illness or treatment. The effect of treatment of the patient with broad-spectrum antibiotics on the Alere Determine TB LAM Ag test performance has not been established.

    CONTENTS

    AlereDetermineTBLAMAgTestCard,10cards(10tests/card)

    ACCESSORIES (required but not provided)Urine collection cups

    A60lMICROSAFE CAPILLARY TUBE (7D2224)

    EQUIPMENT (required but not provided)

    Pipettecapableofaccuratelydelivering60Landdisposablepipettetips.Timer

    WARNINGS AND PRECAUTIONS

    For In Vitro diagnostic use. For professional use only.Safety data sheet available for professional user on request.

    CAUTION:

    Any clinical specimen from any patient should be considered potentially infectious material and has to be handled according to institutional guidelines for handling such materials.

    Appropriate biosafety practices3,4 should be used when handling specimens and reagents. These precautions include, but are not limited to the following:

    Weargloves.Donotpipettebymouth.Donoteat,drink,smoke,applycosmetics,orhandlecontactlensesinareaswherethesematerials

    are handled.

    Cleananddisinfectallspillsofspecimensorreagentsusingsuitabledisinfectant,suchas0.5%sodium hypochlorite, or other suitable disinfectant.3

    Decontaminateanddisposeofallspecimens,reagents,andotherpotentiallycontaminatedmaterialsin accordance with local regulations.3,4

    STORAGE

    Alere DetermineTBLAMAgtestcardsmustbestoredat2-30Cuntiltheexpirationdate.Kitcomponentsarestableuntilexpirationdatewhenhandledandstoredasdirected.Donotusekit

    components beyond expiration date.

    Immediatelyresealallunusedtestsinthefoilpouchcontainingthedesiccantbypressingsealfromend to end to close.

    Donotusedevicesthathavebecomewetorifthepackaginghasbecomedamaged.

    SPECIMEN COLLECTION

    Prior to urine collection cleaning of the urogenital area with clean wipe is recommended. Collect midstream urine in a fresh standard urine collection container.

    SPECIMEN STORAGE

    Freshurinesamplescanbeusedwithin8hoursifkeptatroomtemperature.Urinesamplesshouldbestoredat2-8Cifthetestistoberunwithin3daysofcollection.Iftestingisdelayedmorethan3days,thesamplesshouldbefrozen(-20Corcolder).

    Forfrozenorrefrigeratedurinebringallsamplestoroomtemperatureonehourpriortouse.Frozensamplesmaycontainaggregates.Allthawedsamplesmustbecentrifugedat10,000gfor5minutesatroomtemperatureandthe60Ltestsampleshouldbecarefullycollectedfromtheclearsupernatant.

    Avoidrepeatedfreeze/thawcycles.Specimensthathavebeenfrozenandthawedmorethan3timescannot be used.

    TB LAM AgDetermine

    December201302740004/05

    TEST PROCEDURE

    Thedesirednumberoftestunitsfromthe10-testcardcanberemovedbybendingandtearingattheperforation.

    NOTE: Removalofthetestunitsshouldstartfromtherightsideofthetestcardtopreservethelotnumber

    which appears on the left side of the test card.

    Theassayshouldbeinitiatedwithin2hoursafterremovingtheprotectivefoilcoverfromeachtest.

    1. Remove the protective foil cover from each test.2. Apply60Lofsample(precisionpipette)tothesamplepad(Whitepadmarkedbythearrow

    symbol).A60lMICROSAFE CAPILLARY TUBE can be used (refer to the Microsafe Capillary Tube package insert for additional information).

    3. Wait a minimum of 25 minutes and read result. Visualize the strip under standard indoor lighting conditions or in the shade. Do not visualize the strip under direct sun light. Results are stable for up to 35 minutes after sample application. Do not read beyond 35 minutes.

    QUALITY CONTROL

    To ensure assay validity, a procedural control is incorporated in the device and is labeled Control. If the control bar does not turn purple/gray by assay completion, the test result is invalid and the sample should be retested.

    INTERPRETATION OF RESULTS

    To assist with results reading and interpretation use the Reference Scale Card (provided in the kit) by holding it alongside the patient window.

    LAM Antigen POSITIVE (Two Bars - Control and Patient Bars)

    Purple/gray bars appear in both the control window (labeled Control) and the Patient window (labeled Patient) of the strip. The color intensity of the Patient bar should be equal to, or stronger than, any of the colored bars in the POSITIVE range on the Reference Scale Card.

    Note: The test result is positive even if the patient bar appears lighter or darker than the control bar, as long as the Patient bar is equal to or stronger than any of the colored bars in the POSITIVE range on the Reference Scale Card.

    NEGATIVE (One Bar)

    One purple/gray bar appears in the control window of the strip (labeled Control) and no purple/gray bar appears in the Patient window of the strip (labeled Patient).

    INVALID (No Bar)

    If there is no purple/gray bar in the control window of the strip, even if a purple/gray bar appears in the patient window of the strip, the result is invalid and the test should be repeated. If the problem persists, contact your local distributor or call Alere Technical Support as detailed below.

    EQUIVOCAL/INDEFINITE:

    One purple/gray bar appears in the Control window of the strip (labeled Control) with unclear or incomplete purple/gray bar in the Patient window of the strip (labeled Patient) OR: if the color intensity of the bar in the Patient window is lower than any of the colored bars in the POSITIVE range on the Reference Scale Card. For a better clinical decision the test should be repeated. Alternatively, collect a new urine sample from the patient in the following days and test. First or early morning urine is recommended.

    PERFORMANCE CHARACTERISTICS

    The performance of Alere Determine TB LAM Ag test has been determined by testing urine specimens from HIV positive patients with suspected TB infection. The performance evaluations were conducted in prospective clinical studies in South Africa.

    Prospective study versus sputum culture

    The diagnostic accuracy of the Alere Determine TB LAM Ag for screening for HIV-associated pulmonary tuberculosis was evaluated in a prospective study in HIV infected outpatients newly referred to ART (antiretroviral therapy) clinic in Cape Town, South Africa5.

    Of516patientswithcompletedatainformation,85hadpositiveTBdiagnosisbasedonpositiveTBsputum culture. The Alere Determine TB LAM Ag sensitivity compared to sputum culture was strongly associated with the patients CD4 cell count with the highest sensitivity at low CD4 cell counts: 66.7%at

  • 3TB LAM AgDetermine

    ESLea detenidamente este prospecto antes de usar el dispositivo y siga las instrucciones recogidas en el mismo. Debe respetar escrupulosamente las instrucciones de este prospecto.

    NOMBRE Y USO PREVISTO

    La prueba Alere Determine TB LAM Ag es un inmunoanlisis cualitativo in vitro de lectura visual, que ha sido diseado para detectar el antgeno lipoarabinomannan (LAM) de las micobacterias en la orina humana y facilitar el diagnstico de la infeccin micobacteriana activa en sujetos con VIH positivo que presentan sntomas clnicos de tuberculosis.

    INTRODUCCIN

    La tuberculosis (TB) es una enfermedad multifactica y un importante problema de salud pblica tanto en los pases industrializados como en los pases en vas de desarrollo. En la actualidad, los programas de control de la TB se enfrentan a un gran nmero de restricciones. En todo el mundo, se detectan menos del 25% de todos los casos de tuberculosis. Mucho ms preocupante es la ausencia de una prueba precisa y rpida que diagnostique la enfermedad micobacteriana. El diagnstico precoz es clave para evitar la expansin de la TB1.

    Las pruebas diagnsticas estndar de TB que se utilizan actualmente adolecen de ciertas carencias bien documentadas. Incluso en entornos de investigacin controlados, la sensibilidad media de la muestra de esputo al microscopio para la tuberculosis pulmonar solo es del 67% y es sustancialmente inferior entre sujetos infectados con VIH2. Los mtodos de cultivo convencionales son tan lentos, que con frecuencia los anlisis pierden importancia clnica. Adems, el escaso valor de prediccin de la prueba cutnea de la tuberculina hace que sta no sea de utilidad en regiones endmicas. Los puntos dbiles de las tecnologas diagnsticas disponibles solo aumentan en pases con mayor nmero de casos, en los que normalmente no se dispone de las infraestructuras y el personal adecuado. Adems, los ensayos microbiolgicos basados en muestras de esputo no pueden detectar infecciones de TB extrapulmonar, una manifestacin clnica que aparece ms frecuentemente en las regiones endmicas con un mayor nmero de infectados por VIH. Otro obstculo importante es el diagnstico de la tuberculosis en nios. Es habitual que la incapacidad de los nios pequeos para generar esputo dificulte los mtodos basados en el anlisis de muestras de esputo. La prueba Alere Determine TB LAM Ag solo precisa de una muestra de orina y se realiza en 25 minutos.

    PRINCIPIOS BIOLGICOS DEL PROCEDIMIENTO

    La prueba Alere Determine TB LAM Ag es un anlisis inmunocromatogrfico diseado para la deteccin cualitativa del antgeno lipoarabinomannan (LAM) de las micobacterias en orina humana. La prueba Alere Determine TB LAM Ag emplea anticuerpos altamente purificados, especficos del principal antgeno polisacrido del gnero Mycobacterium: lipoarabinomannan (LAM). Estos anticuerpos se utilizan tanto como trazadores de captura como de deteccin. Los anticuerpos de captura se absorben en la membrana de nitrocelulosa de las tiras reactivas. El anticuerpo de deteccin se marca con un conjugado de partculas de oro coloidal.

    Una vez que la muestra de orina se haya agregado a la seccin de muestra, los anticuerpos conjugados con oro coloidal se adhieren al antgeno LAM y la muestra los libera de la seccin de conjugado. A continuacin, los anticuerpos anti-LAM, inmovilizados en la membrana de nitrocelulosa, capturan este complejo inmunolgico que se hace visible gracias a la presencia del marcador de oro coloidal. Un resultado positivo (una banda visible de color prpura/gris) indica que el antgeno LAN de las micobacterias est presente en la muestra en el lmite de deteccin de la prueba o por encima de l. Un resultado negativo (sin banda visible de color prpura/gris) indica que ste no est presente o que se encuentra por debajo del lmite de deteccin. Con el fin de garantizar la validez del ensayo, se ha incorporado una banda de control del procedimiento en el dispositivo del ensayo.

    LIMITACIONES DEL ENSAYO

    LapruebaAlere Determine TB LAM Ag se ha diseado para detectar el antgeno LAM micobacteriano en orina humana. No se deben utilizar otras muestras, tales como esputo, suero, plasma, lquido cefalorraqudeo u otros fluidos corporales, ni muestras de orina combinadas.

    LapruebaAlere Determine TB LAM Ag no diferencia las diversas especies de micobacterias tales como M. tuberculosis, M. leprae o M. avium. En las regiones endmicas de tuberculosis, es probable que los antgenos LAM detectados en las muestras clnicas puedan atribuirse a M. tuberculosis.

    NingunapruebagarantizaalcienporcienqueunamuestranocontienenivelesbajosdelantgenoLAM como los que se manifiestan en las primeras fases de la enfermedad. Un resultado negativo no descarta la posibilidad de infeccin por M. tuberculosis.

    Ningunapruebaes100%especfica.Losresultadospositivosdebenevaluarseenconjuntoconelexamen clnico general antes de concluir el diagnstico.

    LapruebaAlere Determine TB LAM Ag debe confirmarse con otras pruebas tales como el cultivo bacteriano y, cuando sea posible, con una prueba de susceptibilidad a los frmacos.

    Laintensidaddelcolordelabandadepacientenotienecorrelacinnecesariamenteconlacargabacteriana.

    LosanlisisdeorinadiurticapuedeninfluirenlacapacidaddelapruebaparadetectarlosantgenosLAM en la orina de pacientes con TB.

    LaexcrecindelantgenoLAMenlaorinapuedevariarenfuncindelestadodecadapacienteyla enfermedad o tratamiento subyacentes. No se ha determinado cmo puede afectar el uso de antibiticos de amplio espectro al rendimiento de la prueba Alere Determine TB LAM Ag.

    CONTENIDO

    Tarjeta de anlisis de la prueba AlereDetermineTBLAMAg,10tarjetas(10pruebasportarjeta).

    ACCESORIOS (necesarios pero no incluidos)Vasos de recoleccin de orina

    A60lMICROSAFE CAPILLARY TUBE (7D2224)MATERIALES (necesarios pero no incluidos)Pipetacapazdedispensarconprecisin60lypuntasdesechablesdepipeta.Temporizador

    ADVERTENCIAS Y PRECAUCIONES

    Para uso diagnstico in vitro.Solo para uso profesional.La hoja de datos de seguridad se encuentra disponible para los profesionales que la soliciten.

    PRECAUCIN:

    Todas las muestras clnicas de pacientes deben considerarse como material potencialmente infeccioso, por lo que deben manipularse segn lo estipulado en las directrices institucionales a tal respecto.Deben seguirse las normas de bioseguridad3,4, cuando se manipulen muestras y reactivos. A continuacin se enumeran algunas de estas precauciones:Lleveguantes.Nopipeteeconlaboca.Nocoma,beba,fume,apliqueproductoscosmticosomanipulelentesdecontactoenlaszonas

    prximas en las que se utilizan estos materiales.

    Limpieydesinfectetodoslosderramesdemuestrasoreactivosutilizandoundesinfectanteadecuado,comounasolucindehipocloritodesodioal0,5%.3

    Descontamineydesechetodaslasmuestrasyotrosmaterialespotencialmentecontaminadosdeconformidad con las normativas locales.3,4

    CONSERVACIN

    Las tarjetas de anlisis de la prueba Alere Determine TB LAM Ag deben almacenarse a una temperaturadeentre2y30Chastalafechadecaducidad.Loscomponentesdelkitestarnestableshastalafechadecaducidadsisemanipulanyconservan

    tal como se indica. No utilice los componentes del kit una vez superada la fecha de caducidad.

    Vuelvaaintroducirdeinmediatolaspruebasquenohayautilizadoenlabolsadealuminioquecontiene el desecante y sllela de un extremo a otro para cerrarla.

    Noutilicelosdispositivosquesehayanhumedecidoocuyoembalajehayaresultadodaado.

    OBTENCIN DE LA MUESTRA

    Antes de recoger la muestra de orina, se recomienda limpiar la zona genitourinaria con una toalla limpia. Recoja la orina en un recipiente estndar de recoleccin de orina fresca.

    CONSERVACIN DE LA MUESTRA

    Siseconservanatemperaturaambiente,lasmuestrasdeorinafrescapuedenutilizarsealolargodelas8horassiguientesasuobtencin.

    Sielanlisissevaarealizaralolargodelos3dasposterioresalaobtencindelasmuestradeorina,stasdebenalmacenarseaunatemperaturadeentre2y8C.Sielanlisissevaretrasarmsde3das,sedebencongelarlasmuestras(a-20Comenos).

    Silasmuestrasestncongeladasorefrigeradas,sehandeponeratemperaturaambienteunahoraantes de utilizarlas.

    Lasmuestrascongeladaspuedenconteneragregados.Todaslasmuestrascongeladassedebencentrifugara10.000gdurante5minutosatemperaturaambiente.Adems,lamuestradepruebade60lsedeberecogerconcuidadodelsobrenadantetransparente.

    Eviteciclosdecongelado/descongeladorepetidos.Nosepuedenutilizarlasmuestrasquesehayancongelado y descongelado ms de tres veces.

    PROCEDIMIENTO DEL ANLISIS

    Elnmerodeseadodeunidadesdepruebadelas10tarjetasdeanlisispuedenextraersedoblandoorasgando la perforacin.

    NOTA: Laextraccindelasunidadesdepruebadebeiniciarseenellateralderechodelatarjetadeanlisis

    con el fin de conservar el nmero de lote que aparece en el lateral izquierdo de sta.

    Elanlisisdebeiniciarsealolargodelas2horasposterioresalaretiradadelacubiertaprotectoradealuminio de cada prueba.

    1. Retire la cubierta protectora de aluminio de cada prueba.2.Aplique60ldelamuestra(pipetadeprecisin)alaseccindemuestra(seccinblancamarcada

    con el smbolo de la flecha). LaA60lMICROSAFE CAPILLARY TUBE se puede utilizar (para obtener informacin adicional, consulte el prospecto del envase del tubo capilar Microsafe).

    3. Espere un mnimo de 25 minutos y lea el resultado. Visualice la tira en un entorno con una iluminacin interior estndar o en la sombra. No la visualice bajo la luz directa del sol. Los resultados permanecen estables hasta unos 35 minutos despus de haber aplicado la muestra. Si han transcurrido ms de 35 minutos no lea los resultados de la muestra.

    CONTROL DE CALIDAD

    Para garantizar la validez del ensayo, se ha incorporado un control de procedimiento en el dispositivo etiquetado como Control. Si, una vez acabado el ensayo, la banda de control no torna a un color prpura/gris, el resultado de la prueba no es vlido y no se debe volver a analizar la muestra.

    INTERPRETACIN DE LOS RESULTADOS

    Para facilitar la lectura e interpretacin de los resultados utilice la Tarjeta de Escala de Referencia (incluida en el kit) y sostngala junto a la ventana de paciente.

    Antgeno LAM POSITIVO (dos bandas: bandas de control y de paciente)

    Las bandas de color prpura/gris aparecen tanto en la ventana de control (etiquetada como "Control") como en la ventana de paciente (etiquetada como "Paciente") de la tira.La intensidad del color de la barra del Paciente debe ser igual o ms fuerte que cualquiera de las barras de colores en el rango POSITIVO de la Tarjeta de Escala de Referencia.

    Nota: El resultado de la prueba es positivo incluso aunque la banda de paciente sea de un color ms tenue u oscuro que el de la banda de control, siempre y cuando la barra del Paciente sea igual o ms fuerte que cualquiera de las barras de colores en el rango de POSITIVO de la Tarjeta de Escala de Referencia.

    NEGATIVO (una banda)

    Aparece una banda de color prpura/gris en la ventana de control de la tira (etiquetada como "Control"), mientras que en la ventana de paciente (etiquetada como "Paciente") no aparece ninguna banda de color prpura/gris.

    NO VLIDA (sin franja)

    Aunque en la ventana de paciente de la tira aparezca una banda prpura/gris, si en la ventana de control de la tira no aparece ninguna banda de estos colores, el resultado no es vlido y la prueba no debe repetirse. Si el problema persiste, pngase en contacto con su distribuidor local o llame al Servicio de asistencia tcnica de Alere al alguno de los nmeros de telfono que se muestran a continuacin.

    EQUVOCO/INDEFINIDO:

    Aparece una banda de color prpura/gris en la ventana de control de la tira (etiquetada como "Control") y una banda incompleta o poco clara de color prpura/gris en la ventana de paciente de la tira (etiquetada "Paciente") O: si la intensidad del color de la barra en la ventana Paciente es menor que cualquiera de las barras de colores en el rango de POSITIVO de la Tarjeta de Escala de Referencia.Para obtener una mejor decisin clnica, debe repetir la prueba. Como mtodo alternativo, recoja una nueva muestra de orina del paciente en los das siguientes y analcela. Se recomienda que la muestra sea de la primera orina de la maana.

    CARACTERSTICAS DE DESEMPEO

    El desempeo de la prueba Alere Determine TB LAM Ag ha sido determinado mediante el anlisis de muestras de orina de pacientes VIH positivos con sospecha de infeccin de tuberculosis. Lasevaluaciones de desempeo se llevaron a cabo en estudios clnicos prospectivos en Sudfrica.

    Estudio prospectivo frente a cultivo de esputo

    La precisin diagnstica de Alere Determine TB LAM Ag para la deteccin de tuberculosis pulmonar asociada con VIH fue evaluada en un estudio prospectivo en pacientes ambulatorios con infeccin de VIH recin remitidos a una clnica de terapias antirretrovirales en Ciudad del Cabo, Sudfrica5.

    De516pacientesconinformacindedatoscompleta,85tuvierondiagnsticopositivodetuberculosisbasado en el cultivo de esputo de TB positiva. La sensibilidad de Alere Determine TB LAM Ag en comparacin con el cultivo de esputo estuvo fuertemente asociada con el recuento de clulas CD4 delospacientesconmayorsensibilidadenbajosrecuentosdeclulasCD4:66,7%a

  • 4TB LAM AgDetermine

    FRLire attentivement cette notice avant utilisation. Suivre les instructions qui y figurent. Il nest pas possible de droger aux instructions fournies.

    NOM ET INDICATION

    Alere Determine TB LAM Ag est un immunodosage in vitro qui permet la dtection qualitative de lantigne lipoarabinomannane (LAM) des mycobactries dans lurine humaine avec prsentation visuelle des rsultats. Il est utilis pour le diagnostic des infections mycobactriennes actives chez les patients sropositifs prsentant des symptmes cliniques de tuberculose.

    INTRODUCTION

    La tuberculose (TB) est une maladie nombreuses facettes qui pose un problme majeur de sant publique aussi bien dans les pays industrialiss que dans les pays en dveloppement. Les programmes de contrle de la TB sont actuellement confronts un certain nombre dobstacles. Moins de 25 % des cas de tuberculose sont dtects dans le monde entier. Labsence de tests prcis en temps voulu permettant le diagnostic des maladies mycobactriennes constitue notre principale proccupation. Le diagnostic prcoce de la TB est primordial afin dviter la propagation de la maladie1.

    Les tests diagnostiques standard actuels de la TB prsentent plusieurs faiblesses bien documentes. Mme dans les cadres de recherche contrls, la sensibilit moyenne de lexamen microscopique des expectorations pour la tuberculose pulmonaire est de seulement 67 % et est considrablement plus faible chez les patients sropositifs2. Les mthodes de culture conventionnelles sont si lentes que les tests perdent souvent toute pertinence clinique. Par ailleurs, la faible valeur prdictive du test cutan la tuberculine rend celui-ci fondamentalement inutile dans les zones endmiques. Les faiblesses des technologies diagnostiques disponibles sont encore exacerbes dans les pays les plus touchs, qui souffrent gnralement de linsuffisance des infrastructures et des effectifs. Par ailleurs, les dosages microbiologiques bass sur les expectorations sont incapables de dtecter la TB extra-pulmonaire, une manifestation clinique plus frquente dans les zones de forte endmie de VIH. Le diagnostic de la tuberculose chez les enfants constitue un autre obstacle important. Les mthodologies bases sur les expectorations ptissent souvent de lincapacit des jeunes enfants en produire. Alere Determine TB LAM Ag ne ncessite quun chantillon durine et produit des rsultats en 25 minutes.

    PRINCIPES BIOLOGIQUES DE LA PROCDURE

    Alere Determine TB LAM Ag est un test immunochromatographique qui permet la dtection qualitative de lantigne lipoarabinomannane (LAM) des mycobactries dans lurine humaine. Alere Determine TB LAM Ag repose sur des anticorps hautement purifis, spcifiques au principal antigne polysaccharidique du genre Mycobacterium : lipoarabinomannane (LAM). Ces anticorps sont utiliss la fois pour la capture et la dtection. Les anticorps de capture sont adsorbs sur la membrane en nitrocellulose de la bandelette. Lanticorps de dtection est marqu (conjugu) des particules dor collodal.

    Lorsquun chantillon urinaire est ajout au tampon chantillon, les anticorps conjugus lor collodal se fixent sur lantigne LAM et sont librs par lchantillon du tampon conjugu. Ce complexe immunologique est ensuite captur par les anticorps anti-LAM fixs sur la membrane en nitrocellulose et mis en vidence par le marquage lor collodal. Un rsultat positif (illustr par la prsence dune bande gris pourpre) indique que lantigne LAM mycobactrien est prsent dans lchantillon en quantit gale ou suprieure la limite de dtection du test, tandis quun test ngatif (illustr par labsence de bande gris pourpre) indique que lantigne est absent ou en quantit infrieure la limite de dtection. Pour garantir la validit du dosage, une barre de contrle de la procdure est incorpore au dispositif de dosage.

    LIMITES DE LA PROCDURE

    Alere Determine TB LAM Ag est conu pour dtecter lantigne LAM mycobactrien dans lurine humaine. Il est dconseill dutiliser dautres types dchantillons (notamment les expectorations, le srum, le plasma, le LCR ou les autres liquides corporels), y compris des chantillons combins durine.

    Alere Determine TB LAM Ag ne permet pas de faire la distinction entre les diffrentes espces de Mycobacterium, telles que M. tuberculosis, M. leprae, et M. avium. Dans une zone endmique de tuberculose, lorsquun antigne LAM est dtect dans un chantillon clinique, il est susceptible dtre spcifique de M. tuberculosis.

    Aucuntestnefournitlassuranceabsoluequunchantillonnecontientpasdefaiblesquantitsdantigne LAM comme cest le cas un stade prcoce de linfection. Un rsultat ngatif nexclut pas la possibilit dune infection M. tuberculosis.

    Aucuntestnestspcifique100%.Lesrsultatspositifsdoiventtreinterprtslalumiredelvaluation clinique globale avant de poser un diagnostic.

    Sipossible,Alere Determine TB LAM Ag doit tre suivi dun test de confirmation, tel quune culture bactrienne, et dun test de sensibilit aux mdicaments.

    Lintensitdelabarrepatientnestpasncessairementcorrlelachargebactrienne.LutilisationdediurtiquesestsusceptibledaffecterlacapacitdutestdtecterlantigneLAM

    dans lurine des patients tuberculeux.

    LexcrtiondelantigneLAMdanslurinepeutvarierselonlaconditionindividuelledupatient,samaladie sous-jacente ou son traitement. Leffet dun traitement antibiotique large spectre sur la performance du test Alere Determine TB LAM Ag na pas t tabli.

    CONTENU

    Carte-test AlereDetermineTBLAMAg,10cartes(10tests/carte).

    ACCESSOIRES (ncessaires mais non fournis)

    Gobelets de collecte urinaire

    Un60lMICROSAFE CAPILLARY TUBE (7D2224)QUIPEMENT (ncessaire mais non fourni)Pipettedeprcisiondunecontenancede60letemboutsdepipettejetables.Minuteur

    MISES EN GARDE ET PRCAUTIONS DEMPLOI

    usage diagnostic in vitro.Rserv un usage professionnel.Une fiche de donnes de scurit est disponible sur demande pour les professionnels.

    MISE EN GARDE:

    Tout chantillon clinique provenant dun patient est potentiellement infectieux et doit tre manipul conformment aux directives de ltablissement concernant ce type de matriau.Utiliser les pratiques appropries en matire de bioscurit3,4 lors de la manipulation dchantillons et deractifs.Cesprcautionsincluentnotammentlesrglessuivantes:Porterdesgants.Nepaspipeterlabouche.Nepasmanger,boire,fumer,appliquerdeproduitscosmtiquesoumanipulerdeslentillesdecontact

    dans les zones de manipulation des chantillons et des ractifs.

    Nettoyeretdsinfectertoutdversementdchantillonsouderactifsavecundsinfectantadapt,telquunesolutiondhypochloritedesodium0,5%.3

    Dcontamineretmettreaurebuttousleschantillonsainsiquetoutautrematrielsusceptibledavoirt contamin conformment aux rglementations locales en vigueur.3,4

    CONSERVATION

    Conserver les cartes de test Alere DetermineTBLAMAgentre2et30Cjusquladatedepremption.Lescomposantsdelatroussesontstablesjusquladatedepremptionlorsquilssontmanipulset

    conservs conformment aux instructions. Ne pas utiliser les composants de la trousse au-del de la date de premption.

    Refermerimmdiatementlapochettehermtiqueenaluminiumcontenantlesachetanti-condensationdans laquelle se trouvent tous les tests inutiliss en appuyant fermement dun bout lautre de louverture.

    Nepasutiliserlesdispositifshumidesoudontlemballageestendommag.

    COLLECTE DES CHANTILLONS

    Avant de collecter les urines, il est recommand de nettoyer la zone urognitale laide dune lingette propre. Collecter lurine mi-miction dans un rcipient de collecte urinaire standard neuf.

    CONSERVATION DES CHANTILLONS

    Leschantillonsurinairesfraisconservstempratureambiantesontutilisablespendant8heures.Leschantillonsurinairesconservsunetempraturecompriseentre2et8Csontutilisables

    jusqu3joursaprslacollecte.Siletestestprvuau-delde3jours,congelerleschantillons(unetempratureinfrieureougale-20C).

    Encasdutilisationdurinecongeleourfrigre,placertousleschantillonstempratureambianteune heure avant leur utilisation.

    Leschantillonscongelssontsusceptiblesdecontenirdesagrgats.Centrifugertousleschantillonsdcongels10000gpendant5minutestempratureambiante.Prleversoigneusementunchantillonde60lpartirdusurnageantlimpide.

    viterlescyclesrptsdeconglation/dconglation.Nepasutiliserdchantillonsayanttcongelsetdcongelsplusde3fois.

    PROCDURE DU TEST

    Dtacherlaquantitsouhaitedunitsdetestdelacarte10testsenpliantetendchirantlelongdela perforation.

    REMARQUE: Commencerdtacherlesunitsdetestparladroitedelacartedetestspourprserverlenumro

    de lot qui se trouve sur la gauche de la carte.

    Commencerledosageauplustard2heuresaprsavoirretirlecouvercleenaluminiumdechaquetest.

    1. Retirer le couvercle en aluminium de chaque test.2.Appliquerunchantillonde60l(laidedunepipettedeprcision)surletamponchantillon

    (tampon blanc marqu dune flche). Un60lMICROSAFE CAPILLARY TUBE peut tre utilis (consulter la notice dutilisation du capillaire Microsafe pour plus dinformations).

    3.Attendreaumoins25minutesavantdelirelersultat.Visualiserlabandelettedansdesconditionsdclairage intrieur standard ou lombre. Ne pas visualiser la bandelette la lumire directe du soleil.Lesrsultatssontstablespendant35minutesaprslapplicationdelchantillon.Nepaslirelersultatau-delde35minutes.

    CONTRLE QUALIT

    Pour garantir la validit du dosage, un contrle de la procdure (annot Control ) est incorpor au dispositif. Si la barre de contrle ne devient pas gris pourpre dici la fin du dosage, le rsultat du test est non valide et le test doit tre rpt.

    INTERPRTATION DES RSULTATS

    Pour faciliter la lecture et linterprtation des rsultats, utiliser la carte dchelle de rfrence (fournie dans la trousse) en la plaant le long de la fentre patient.

    AntigneLAM:POSITIF(deuxbarres:barredecontrleetbarrepatient)

    Deux barres gris pourpre apparaissent sur la bandelette : lune dans la fentre de contrle (annote Control ) et lautre dans la fentre patient (annote Patient ). Lintensit de la couleur de la barre Patient doit tre gale ou plus marque que toutes les autres barres colores dans la zone POSITIF de la carte dchelle de rfrence.

    Remarque : le rsultat du test est positif mme si la barre patient est plus claire ou plus fonce que la barre de contrle, aussi longtemps que la barre Patient est gale ou plus marque que toutes les autres barres colores dans la zone POSITIF de la carte dchelle de rfrence.

    NGATIF (une barre)

    Une barre gris pourpre apparat dans la fentre de contrle delabandelette(annoteControl).Aucunebarrenapparat dans la fentre patient de la bandelette (annote Patient).

    NON VALIDE (aucune barre)

    Lorsquaucune barre gris pourpre napparat dans la fentre de contrle de la bandelette, le rsultat est non valide et le test doit tre rpt, mme lorsquune barre gris pourpre apparat dans la fentre patient de la bandelette. Si le problme persiste, contacter le distributeur local ou appeler le service technique Alere aux coordonnes ci-dessous.

    QUIVOQUE/INCERTAIN

    Une barre gris pourpre apparat dans la fentre de contrle de la bandelette (annote Control ), mais la barre qui apparat dans la fentre patient de la bandelette (annote Patient ) OU: si lintensit de la couleur de la barre dans la fentre Patient est moins marque que toutes les autres barres colores dans la zone POSITIF de la carte dchelle de rfrence. Est estompe ou incomplte. Rpter le test pour garantir une bonne prise de dcision clinique. Sinon, collecter un nouvel chantillon urinaire dans les jours qui suivent et rpter le test. Il est recommand dutiliser les premires urines du matin.

    CARACTRISTIQUES DE PERFORMANCE

    La performance du test Alere Determine TB LAM Ag a t dtermine en testant des chantillons durine provenant de patients sropositifs avec suspicion de tuberculose. Les valuations deperformance ont t menes dans des tudes cliniques prospectives en Afrique du Sud.

    tude prospective versus culture des crachats

    La prcision de diagnostic du test Alere Determine TB LAM Ag pour le dpistage de la tuberculose pulmonaire associe au VIH a t value dans une tude prospective chez des patients sropositifs en ambulatoire rcemment dirigs vers une clinique du Cap, Afrique du Sud, pour la mise en place dune thrapie antirtrovirale (ART)5.

    Sur les 516 patientspourlesquelsondisposededonnescompltes,85prsentaientundiagnosticpositif pour la tuberculose, tabli sur la base dune culture de crachat positive. La sensibilit du test Alere Determine TB LAM Ag par rapport celle de la culture des crachats tait fortement lie la numration des cellules CD4 des patients, avec une sensibilit particulirement leve pour les numrationsencellulesCD4peuleves:66,7%si

  • PTAntes da utilizao, deve ler cuidadosamente o folheto informativo. As instrues do folheto informativo devem ser seguidas em conformidade. No so permitidos quaisquer desvios das instrues do folheto informativo.

    NOME E UTILIZAO PREVISTA

    Alere Determine TB LAM Ag um imunoensaio qualitativo In Vitro, de leitura visual, para a deteco do antignio lipoarabinomanano (LAM) da Micobactria na urina humana para ajuda ao diagnstico de infeco activa por micobactria em indivduos HIV-positivos com sintomas clnicos de tuberculose.

    INTRODUO

    A Tuberculose (TB) uma doena multifacetada e um desafiante problema de sade pblica nos pases industrializados e em desenvolvimento. Os planos de controlo da TB enfrentam actualmente vrios condicionalismos. Mundialmente, menos de 25% de todos os casos de tuberculose so detectados. A maior preocupao a ausncia de um teste opurtuno e preciso para diagnosticar a infeco por Micobactria. O diagnstico precoce essencial para prevenir o aumento futuro da TB1.

    Os testes actuais padro para diagnstico da TB possuem vrios pontos fracos documentados. Mesmo em contextos de investigao controlados, a sensibilidade mdia da microscopia da expectorao para a tuberculose pulmonar apenas de 67% e substancialmente menor em pessoas infectadas com o HIV2. Os mtodos de cultura convencionais so to lentos que os testes perdem frequentemente a sua relevncia clnica e o valor de fraca capacidade de previso da prova cutnea da tuberculina torna-a intil em regies onde a doena endmica. As fragilidades destes diagnsticos disponveis tornam-se maiores em pases com um elevado ndice desta doena, que normalmente no possuem infra-estruturas e pessoal clnico adequados. Alm disso, as anlises microbiolgicas da expectorao so incapazes de detectar uma infeco por tuberculose extrapulmonar, uma manifestao clnica que ocorre com mais frequncia em regies endmicas de alta concentrao de HIV. Outro grande obstculo o diagnstico da tuberculose em crianas. Os mtodos baseados na expectorao so frequentemente dificultados devido incapacidade que as crianas mais pequenas tm em produzir expectorao. Alere Determine TB LAM Ag requer apenas de uma amostra de urina e efectuado em 25 minutos.

    PRINCPIOS BIOLLGICOS DO TESTE

    Alere Determine TB LAM Ag um teste imunocromatogrfico para a deteco do antignio lipoarabinomanano (LAM) da Micobactria na urina humana. Alere Determine TB LAM Ag utiliza anticorpos altamente purificados especficos para a maior parte dos antignios polissacardeos do gneroMicobactria: lipoarabinomanano (LAM). Esses antignios so utilizados para a captura e deteco de marcadores. Os antignios de captura so absorvidos para dentro da membrana de nitrocelulose da tira de teste. O antignio de deteco classificado por conjugao a partculas de ouro coloidal.

    Depois de uma amostra de urina ser adicionada tira de teste, os anticorpos conjugados com ouro coloidal ligam-se ao antignio LAM e so libertados pela amostra da tira conjugada. Esse complexo imunolgico depois capturado pelos anticorpos anti-LAM imobilizados na membrana de nitrocelulose que se torna visvel devido presena da etiqueta de ouro coloidal. Um resultado positivo (uma linha prpura/cinzenta visvel) indica que o antignio LAM da Micobactria se encontra presente na amostra, dentro ou acima do limite de deteco do teste; enquanto um resultado negativo (sem linha prpura/cinzenta visvel) indica que este no se encontra presente ou est abaixo do limite de deteco. Para certificao da validade da anlise, encontra-se incorporada uma barra de controlo procedimental no dispositivo de anlise.

    LIMITAES DO PROCEDIMENTO

    Alere Determine TB LAM Ag foi concebido para detectar o antignio LAM da Micobactria na urina humana. No devem ser utilizadas outras amostras (por exemplo expectorao, soro, plasma, lquido cefalorraquidiano ou outros fluidos corporais) ou amostras com grande quantidade de urina.

    Alere Determine TB LAM Ag no diferencia as vrias espcies de Micobactria, tais como a M. tuberculosis, M. leprae, e M. avium. Numa regio endmica para a tuberculose o antignio LAM detectado numa amostra clnica provavelmente atribudo M. tuberculosis.

    NenhumtestefornececertezaabsolutadequeumaamostranocontembaixosnveisdeantignioLAM, tais como os presentes numa fase inicial da infeco. Um resultado negativo no exclui a possibilidade de infeco com M. tuberculosis.

    Nenhumteste100%preciso.Osresultadospositivosdevemseravaliadostendoemcontaaavaliao clnica geral antes de ser efectuado o diagnstico.

    Alere Determine TB LAM Ag deve ser seguido de um teste de confirmao como uma cultura bacteriolgica ou um teste de susceptibilidade a medicamentos, se possvel.

    Aintensidadedabarradopacientenoserelacionanecessariamentecomacargabacteriolgica.OtesteaurinadiurticapodeafectaracapacidadedotestedetectaroantignioLAMnaurinade

    pacientes com TB.

    AexcreodoantignioLAMnaurinapodevariardependendodacondioindividualdopacienteea sua doena subjacente ou tratamento. O efeito do tratamento do paciente com antibiticos de largo espectro no desempenho do teste Alere Determine TB LAM Ag no foi determinado.

    CONTEDOS

    AlereDetermineTBLAMAgTestCard,10cartes(10testes/carto).

    ACESSRIOS(necessriosmasnofornecidos)

    Recipientes de recolha de urina

    Uma60lMICROSAFE CAPILLARY TUBE (7D2224)EQUIPAMENTO(necessriomasnofornecido)Pipetacomcapacidadedetransferir60Lcomprecisoepontasdepipetadescartveis.Temporizador

    ADVERTNCIAS E PRECAUES

    Parautilizaoemdiagnstico In Vitro.Apenasparautilizaoprofissional.FolhadeDadosdeSeguranadisponvelparautilizaoprofissional,apedido.

    CUIDADO:

    Qualquer amostra clnica de qualquer paciente deve ser considerada como material potencialmente infeccioso e deve ser manuseada de acordo com as normas institucionais de manuseamento de tais materiais.Devem ser utilizadas prticas de biossegurana adequadas3,4 ao manusear amostras e reagentes. Estas precaues incluem, mas no se limitam a:Utilizarluvas.Nopipetarcomaboca.Nocomer,beber,fumar,utilizarcosmticosoumanusearlentesdecontactoemreasondeos

    materiais desse tipo so manuseados.

    Limparedesinfectartodososderramesdeamostrasereagentesutilizandoumdesinfectanteapropriado,comohipocloritodesdioa0,5%,ououtrodesinfectanteapropriado.3

    Descontaminareeliminartodasasamostraseoutrosmateriaispotencialmentecontaminadosemconformidade com os regulamentos locais.3,4

    ARMAZENAMENTO

    Os cartes de teste Alere DetermineTBLAMAgdevemserarmazenadosa2-30Cataoprazodeexpirao de validade.OscomponentesdoKitmantm-seestveisataoprazodeexpiraodevalidadequando

    manuseados e armazenados conforme indicado. No utilizar os componentes do kit depois de expirado o prazo de validade.

    Voltaraselartodosostestesnoutilizadosnabolsadealumnioquecontmodissecantepressionando o fecho de uma extremidade outrapara a fechar.

    Noutilizardispositivoscomhumidadeoucomaembalagemdanificada.

    COLHEITA DA AMOSTRA

    Recomenda-se a limpeza da zona urogenital com um toalhete limpo antes da recolha de urina. A urina recolhida deve ser do meio do fluxo e deve ser armazenada num recipiente estril padro para recolha de urina.

    TB LAM AgDetermine

    ARMAZENAMENTO DA AMOSTRA

    Asamostrasdeurinarecentepodemserutilizadasdentrodeumprazode8horasseforemarmazenadas a uma temperatura ambiente.

    Asamostrasdeurinadevemserarmazenadasa2-8Cseaanliseforefectuadaat3diasapsarecolha.Seaanliseforadiadamaisde3dias,asamostrasdevemsercongeladas(-20Coumaisfrio).

    Paraurinacongeladaourefrigeradacolocarasamostrastemperaturaambienteumahoraantesdautilizao.

    Asamostrascongeladaspodemconteragregados.Todasasamostrasdescongeladastmdesercentrifugadasa10000gdurante5minutosaumatemperaturaambienteeaamostraaanalisarde60Ldevesercuidadosamenterecolhidadosobrenadantelimpo.

    Evitarciclosdecongelamento/descongelamentorepetidos.Nopodemserutilizadasamostrasquejforam congeladas e descongeladas mais de 3 vezes.

    PROCEDIMENTO DO TESTE

    Onmerodesejadodeunidadesdetestepodeserretiradodocartode10testesdobrando-oerasgando-o pela perfurao.

    NOTA:

    Aremoodasunidadesdetestedeveiniciar-sepeloladodireitodocartodetestesparapreservaronmerodelote,queseencontranoladoesquerdodocartodetestes.

    Aanlisedeveseriniciadadentrodeduashorasapsaremoodapelculametlicaprotectoradecada teste.

    1. Remover a pelcula metlica protectora de cada teste.2.Aplicar60Ldeamostra(comumapipetadepreciso)nasuperfciedaamostra(superfciebranca

    assinalada com uma seta). Pode ser utilizada uma MICROSAFE CAPILLARY TUBE de60l(para mais informaes consultar o folheto informativo do tubo capilar).

    3. Esperar pelo menos 25 minutos antes da leitura do resultado. Observar a tira sob iluminao interior normal ou sombra. No observar a tira sob a luz solar directa. Os resultados mantm-se estveis at 35 minutos depois da aplicao da amostra. No efectuar a leitura par alm dos 35 minutos.

    CONTROLO DE QUALIDADE

    Para certificao da validade da anlise, est incorporado no dispositivo um controlo de procedimento identificado como Control. Se a barra de controlo no ficar prpura ou cinzenta depois de a anlise estar completa, o resultado do teste invlido e a amostra tem de voltar a ser testada.

    INTERPRETAO DOS RESULTADOS

    Para ajuda com as leituras e interpretaes utilizar o Carto de Escala de Referncia (fornecido com o kit) colocando-o ao lado do visor de paciente.

    POSITIVO ao Antignio LAM (Duas barras - Barra de controlo e de paciente)

    As barras prpura e cinzenta surgem no visor de controlo (identificado como Control) e no visor de paciente (identificado como Patient) da tira. A intensidade da cor da barra do Paciente deve ser igual ou mais forte do que qualquer uma das barras coloridasna faixa POSITIVO do Carto de Escala de Referncia.Nota: O resultado do teste positivo mesmo quando as barras de paciente forem mais claras ou mais escuras que a barra de controlo, contanto que a barra do Paciente seja igual ou mais forte do que qualquer uma das barras coloridas na faixa POSITIVO do Carto de Escala de Referncia.

    NEGATIVO (Uma barra)

    Surge uma barra prpura/cinzenta no visor de controlo da tira (identificado como Control) e no surge nenhuma barra prpura/cinzenta no visor de paciente da tira (identificado como Patient).

    INVLIDO (Sem barras)

    Se no houver nenhuma barra prpura/cinzenta no visor de controlo da tira, mesmo que surja uma barra prpura/cinzenta no visor de paciente da tira, o resultado invlido e o teste deve ser repetido. Em caso de persistncia do problema, contacte o distribuidor local ou ligue para a assistncia tcnica da Alere.

    EQUVOCO/INDETERMINADO:

    Surge uma barra prpura/cinzenta no visor de controlo da tira (identificado como Control) com uma barra prpura/cinzenta pouco clara ou incompleta no visor de paciente da tira (identificado como Patient). OU: se a intensidade da cor da barra na janela Paciente for menor do que qualquer uma das barras coloridas na faixa POSITIVO do Carto de Escala de Referncia. Para uma melhor deciso clnica o teste deve ser repetido. Em alternativa, poder ser recolhida e analisada uma nova amostra de urina do paciente nos dias seguintes. recomendadaautilizaodaprimeiraurinadamanh.

    CARACTERSTICAS DE DESEMPENHO

    O desempenho do teste Alere Determine TB LAM Ag foi determinado por testes em amostras de urina de pacientes HIV-positivos com infeco suspeita de tuberculose. As avaliaes de desempenho foram conduzidas por estudos clnicos prospectivos na frica do Sul.

    Estudo prospectivo e cultura do escarro

    A preciso diagnstica do Alere Determine TB LAM Ag para a triagem de tuberculose pulmonar associada ao HIV foi avaliada num estudo prospectivo em pacientes infectados com HIV, recm designados para incio da TARV (terapia anti-retroviral) na Cidade do Cabo, frica do Sul5.

    De516pacientescominformaesdedadoscompletas,85apresentaramdiagnsticodeTBpositivabaseado na cultura positiva de escarro para a tuberculose. A sensibilidade do Alere Determine TB LAM Ag comparada com a cultura de escarro foi fortemente associada com a contagem de clulas CD4dospacientes,sendomaiorasensibilidadeembaixascontagensdeclulasCD4:66,7%em

  • 6BIBLIOGRAPHY / BIBLIOGRAFA / BIBLIOGRAPHIE / BIBLIOGRAFIA

    1. Diagnostics for tuberculosis: global demand and market potential / TDR, FIND SA.

    2. Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics by thenewdiagnosticsworkinggroupoftheStopTBPartnership.WorldHealthOrganization.2009.

    3. National Committee for Clinical Standards Clinical Waste Management: Approved Guideline. NCCLS DocumentGPS-A.Villanova,PA:NCCLS,1993;13(22):1-18,29-42.

    4. US Environmental Protection Agency EPA Guide for Infections Waste Management: Publication No. EPA/530-SW-86-014.Washington,DC:USEnvironmentalProtectionAgency,1986:1-1-5,R1-R3,A1-A24.

    5.LawnSD,KerkhoffAD,VogtM,WoodR.Diagnosticaccuracyofalow-cost,urineantigen,point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptivestudy.LancetInfectDis.2012Mar;12(3):201-9.

    6.PeterJG,TheronG,vanZyl-SmitR,HaripersadA,MottayL,KrausS,BinderA,MeldauR,HardyA,DhedaK.DiagnosticaccuracyofaurineLAMstrip-testforTBdetectioninHIV-infectedhospitalisedpatients.EurRespirJ.2012Feb23(Epubaheadofprint).

    Advice Line

    For further information, please contact your distributor, or call to one of the following Alere Product

    Support Care Centers:

    Region Phone E-Mail Address

    Europe & Middle East +44(0)1614839032 [email protected] Pacific +(61) 7 3363 7711 [email protected]

    Africa, Russia & CIS +(972)89429683 [email protected]

    Latin America+(57)26618797

    [email protected]+ (57) 317 4424321

    Msinformacin

    Para obtener ms informacin, pngase en contacto con su distribuidor o llame por telfono a alguno

    de los centros de asistencia de productos de Alere que se enumeran a continuacin:

    Regin Telfono Direccin de correo electrnico

    Europa y Oriente Medio +44(0)1614839032 [email protected] y Ocano Pacfico +(61) 7 3363 7711 [email protected]

    frica, Rusia y CIS +(972)89429683 [email protected]

    Latin America+(57)26618797

    [email protected]+ (57) 317 4424321

    Assistance tlphonique

    Pour plus dinformations, contacter le distributeur ou appeler lun des centres de support produit Alere

    suivants:

    Rgion Tlphone Adresse e-mail

    Europe et Moyen-Orient +44(0)1614839032 [email protected] Pacifique + (61) 7 3363 7711 [email protected]

    Afrique, Russie et CEI +(972)89429683 [email protected]

    Latin America+(57)26618797

    [email protected]+ (57) 317 4424321

    Linha de aconselhamento

    Para mais informaes, contacte o seu distribuidor ou ligue para um dos seguintes Centros de

    Atendimento de Apoio a Produtos Alere:

    Regio Telefone Endereo de Correio Electrnico

    Europa e Mdio Oriente +44(0)1614839032 [email protected] e Pacfico + (61) 7 3363 7711 [email protected]

    frica, Rssia e CEI +(972)89429683 [email protected]

    Latin America+(57)26618797

    [email protected]+ (57) 317 4424321

    Urine/Orina/Urine/Urina

    Pipette

    Pipeta

    Pipette

    Pipeta

    Microsafe Capillary Tube

    Tubo capilar Microsafe

    Tube capillaire Microsafe

    Tubo Capilar Microsafe

    The Alere Logo, Alere and Determine are trademarks of the Alere group of companies.2013Alere.Allrightsreserved.

    Orgenics Ltd.6DanSt.,P.O.B.360,Yavne70650,IsraelTel++97289429201Fax++97289438758www.alere.com

    60l 25m/25

    Alere Ltd.Pepper Road, Hazel Grove,Stockport,SK75BW,UK

    02740004_05_black.indd 5 18/12/13 14:13

  • 7D2740

    TB LAM AgDetermine

    Key to symbols used / Smbolos utilizados / Lgende des symboles utiliss / Chave para os smbolos utilizados

    December201302740004/05

    A60lMicrosafeCapillaryTube/A60lTubocapilarMicrosafe/Un60lTubecapillaireMicrosafe/A60lTuboCapilarMicrosafe

    MICROSAFE CAPILLARY TUBEStoreat2-30C/Almacenarentre2y30C/Conserverentre2-30C/Armazenara2-30C

    Orgenics Ltd.6DanSt.,P.O.B.360,Yavne70650,IsraelTel++97289429201Fax++97289438758www.alere.com

    Alere Ltd.Pepper Road, Hazel Grove,Stockport,SK75BW,UK

    02740004_05_black.indd 6 18/12/13 14:13